The Ethereum Foundation and Open Anonymity Project launched zkAPI on October 1, 2026, enabling users to pay for AI and other API services privately on Ethereum mainnet. Users deposit ETH or USDC into a smart contract vault, which converts deposits into credits. Payments for API calls are authorized via zero-knowledge proofs, ensuring transactions cannot be linked back to individual deposits or identities. This system enhances privacy and security, allowing users to control funds independently without relying on centralized servers. The technology is based on cryptographic methods including Groth16 proofs and Merkle trees, and was developed from a concept proposed by Vitalik Buterin earlier in 2026.
The Ethereum Foundation and Open Anonymity Project's launch of zkAPI for private AI access is the subject here. For readers following the broader cryptocurrency market, 30 of 50 major cryptocurrencies on Pluang rose while 19 fell. EOS gained 8.13% to Rp12.649, AAVE rose 6.27% to Rp3.005.550 with a 40% sell and 60% buy split, and DOT declined 3.73% to Rp21.106. These figures are as of Oct 02, 2026 02:41 WIB.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
